Source: Office of Cancer Clinical Proteomics Research
For a copy of the Solicitation and Draft Leidos Agreement please contact:
Matt DeSantis at Matt.Desantis@fnlcr.nih.gov
The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) and the NVIDIA Foundation are pleased to announce funding opportunities in the fight against cancer. Each organization has launched a request for proposals (RFP) that will collectively fund up to $2 million to help to develop a new generation of data-intensive scientific tools to find new ways to treat cancer.
CPTAC is a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of proteomic technologies (using proteogenomic approaches), in order to improve our ability to diagnose, treat and prevent cancer. The NVIDIA Foundation, through its strategic philanthropic initiative Compute the Cure, aims to support cancer researchers in the search for a cure.
Each organization is seeking proposals for projects that leverage computation on integrating large-scale publicly-available omics data sets to dramatically impact the battle against cancer and reduce the time it takes for research outcomes to be used effectively in a clinical environment.
The National Cancer Institute anticipates making up to three awards, with total available funding of $1.8 million. The NVIDIA Foundation will award one project, at up to $200,000.
For additional information about the funding proposal from CPTAC, click here.
For the application and additional information from the NVIDIA Foundation please, click here.
While NCI supports similar goals and objectives as the NVIDIA Foundation’s Compute the Cure initiative, the NCI is not providing support to the NVIDIA Foundation for this initiative or endorsing the Foundation’s activities.
The Antibody Portal serves as a public resource of well-characterized monoclonal antibodies made available by the NCI for the scientific community.